Immunic Aktie

0,6030 EUR +0,0130 EUR +2,20 %

21.11.2025

BMN

0,6990 USD +0,0091 USD +1,32 %

nachbörslich00:39:55

BTT

Immunic jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.71,82 Mio. EUR

Div. Rendite0,00%

WKNA2PHD4

ISINUS4525EP1011

SymbolIMUX

Immunic Aktien News

Sortieren:Datum Meistgelesen

22.02.24PR NewswireImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

15.02.24PR NewswireImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

01.02.24PR NewswireImmunic to Participate in Investor and Scientific Conferences in February

05.01.24PR NewswireImmunic Highlights 2023 Accomplishments and Upcoming Milestones

05.01.24PR NewswireImmunic, Inc. Announces Private Placement of up to $240 Million

21.11.23PR NewswireImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

15.11.23finanzen.netImmunic: Was beim Unternehmen in den jüngsten Büchern steht

14.11.23PR NewswireImmunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07.11.23PR NewswireImmunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update

02.11.23PR NewswireImmunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

26.10.23PR NewswireImmunic to Participate in Scientific and Industry Conferences in November

16.10.23PR NewswireImmunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

15.10.23PR NewswireImmunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

11.10.23PR NewswireImmunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

10.10.23Dow JonesMÄRKTE USA/Aktien starten gut behauptet - Anleihen fest

10.10.23Dow JonesMÄRKTE USA/Aktien gut behauptet erwartet - Anleihen fest

09.10.23PR NewswireImmunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

04.10.23PR NewswireImmunic to Participate in Scientific Conferences in October

06.09.23PR NewswireImmunic to Participate in Industry and Investor Conferences in September

17.08.23PR NewswireImmunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

04.08.23finanzen.netImmunic hat die Zahlen zum jüngsten Quartal vorgelegt

03.08.23PR NewswireImmunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

01.08.23PR NewswireImmunic to Participate in Investor and Scientific Conferences in August

27.07.23PR NewswireImmunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

29.06.23PR NewswireImmunic to Participate in Scientific and Investor Conferences in July

30.05.23PR NewswireImmunic to Participate in Scientific and Investor Conferences in June

17.05.23PR NewswireImmunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

12.05.23finanzen.netImmunic stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor

11.05.23PR NewswireImmunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

09.05.23PR NewswireImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

06.05.23PR NewswireImmunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

04.05.23PR NewswireImmunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

27.04.23PR NewswireImmunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

26.04.23PR NewswireImmunic to Participate in Investor and Scientific Conferences in May

05.04.23PR NewswireImmunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

02.03.23PR NewswireImmunic to Participate in Investor and Scientific Conferences in March

24.02.23finanzen.netImmunic öffnete die Bücher zum abgelaufenen Quartal

23.02.23PR NewswireImmunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

22.02.23PR NewswireImmunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

16.02.23PR NewswireImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.